<i>TFE3</i>-Rearranged and <i>TFEB</i>-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances.

Cancers (Basel) · 2026 · PMC13025244 · PMID 41899560

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

These p -values, while nominally significant, should be interpreted cautiously given the extremely small randomized groups ( n = 6 for nivolumab plus axitinib and n = 5 for nivolumab monotherapy), early trial closure, and inherently unstable point estimates.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

&lt;i&gt;TFE3&lt;/i&gt;-Rearranged and &lt;i&gt;TFEB&lt;/i&gt;-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances.

The sentences

<i>TFE3</i>-Rearranged and <i>TFEB</i>-Altered Renal Cell Carcinomas: Molecular Landscape and Therapeutic Advances.